Orphan Drugs: A Different Breed - 2025 Report
2025 Orphan Drug Report

Report /eBook 2025 Orphan Drug Report : Are Orphans That Different ? By 2030, orphan drugs will make up a fifth of the forecast $1.6 trillion in worldwide prescription drug sales - a share that has doubled over the last decade.

Evaluate's 2025 Orphan Drug Report : Are Orphans That Different ? features extensive insight into the current state of the market, which product indications are performing the best, where the marketplace is currently headed, the R&D pipeline, and more.
Orphan Drugs

A recent analysis, 2025 Orphan Drug Report : Are Orphans That Different ?, by Evaluate Ltd., a business intelligence firm serving the bio/pharmaceutical industry, estimates that by 2030, orphan drugs will make up one-fifth of the forecast $1.6 trillion in worldwide prescription drug sales, a share that has doubled over the last decade.
These mega- orphans have caused the lines between niche and non- orphan drugs to blur, and the lifecycle management techniques used by leading pharmaceutical companies are becoming increasingly evident. The growing awareness of less-prevalent diseases has also inflated overall orphan sales.

Evaluate Releases 2025 Orphan Drug Report
Report reveals orphans' growth advantage over non- orphans is narrowing, begging the question - are these drugs still a class apart? LONDON - 18th March - Evaluate, the leading provider of market insights for the pharmaceutical industry, today released its 2025 Orphan Drug Report highlighting forecasts for the orphan drug market out to 2030.
The 2025 Orphan Drug Report notes that orphan drugs will likely make $320bn by 2030, with Johnson & Johnson taking $31.7bn of this Pharmaceutical market insight specialist Evaluate has debuted its Orphan Drug Report for 2025 , which highlights the recent growth of the sector.

Orphan drugs to make up one fifth of global Rx drug sales by 2030
Pharma market insights provider Evaluate today released its 2025 Orphan Drug Report highlighting forecasts for the orphan drug market out to 2030. The 2025 report , based on Evaluate Pharma forecasts, projects that orphan drugs will make up a fifth of the forecasted $1.6 trillion in worldwide prescription drug sales by 2030.
Key Takeaways Evaluate's Orphan Drug Report 2025 finds sales growth advantage is expected to fall to just 1% by the end of the decade By 2030, these drugs therapies will account for a fifth of all prescription drug sales The growth advantage long enjoyed by orphan drugs over their non- orphan counterparts looks set to slip to just 1% by...

Evaluate releases 2025 Orphan Drug Report
LONDON — Evaluate, a leading provider of market insights for the pharmaceutical industry, has released its 2025 Orphan Drug Report highlighting forecasts for the orphan drug market out to 2030. The 2025 report , based on Evaluate Pharma forecasts, projects that orphan drugs will make up a fifth of the...








This figure refers to medicines that had their orphan designation confirmed by 31 December 2025 . At the time of approval, orphan designations are reviewed by EMA's Committee for Orphan Medicinal Products (COMP) to determine whether the information available to date allows maintaining the medicine's orphan status.